May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.
The company's unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from COVID-19, CSL said in a statement on its website.
CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.
News: CSL Australia's CSL to start work on immunoglobulin product to treat COVID-19
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$280.71 |
Change
-0.215(0.08%) |
Mkt cap ! $135.7B | |||
| Open | High | Low | Value | Volume |
| $281.47 | $282.13 | $279.80 | $13.46M | 47.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 42 | $280.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $280.73 | 2 | 1 |
View Market Depth
| Last trade - 10.30am 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$281.94 |
Change
-0.215 ( 0.47 %) |
||||
| Open | High | Low | Volume | ||
| $281.55 | $282.17 | $279.85 | 1481 | ||
| Last updated 10.47am 27/05/2024 ? | |||||
| CSL (ASX) Chart |